Amyloid; Alzheimer’s: the Cause-and-Effect Question Often Missed
The announcement by Johnson & Johnson and Pfizer that they were pulling the plug on clinical testing of the Alzheimer’s drug bapineuzumab after two failed clinical trials got a lot of mainstream news media coverage – as it should have, to balance some of the earlier breathless hype about the drug’s potential.
But not many stories that we saw got at a core issue. Bloomberg News did a good job when it reported:
While companies have focused on developing drugs to hinder the amyloid deposits, scientists aren’t certain whether the clumps cause or are a minor contributor to the disease or merely a consequence. /.../
No comments:
Post a Comment